All In Biotech

Drug Trial Radar · NCT02633527

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Evaluation of the Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD - A Double-Blind, Placebo-Controlled, Dose-Ranging Study

Last checked: Nov 20, 2026Latest source record: Oct 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

222

Actual

Start

Feb 1, 2016

Primary completion

Jul 25, 2016

Study completion Jul 25, 2016

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with ADHD.

Conditions

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

  • PlaceboDrug

    Placebo was administered once daily

  • 100mg SPN-812Drug

    100mg SPN-812 was administered once daily and compared to placebo

  • 200mg SPN-812Drug

    200mg SPN-812 was administered once daily and compared to placebo

  • 300mg SPN-812Drug

    300mg SPN-812 was administered once daily and compared to placebo

  • 400mg SPN-812Drug

    400mg SPN-812 was administered once daily and compared to placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV)Time frame: Baseline to Week 8 (End of Study)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Florida Clinical Research Center, LLC

    Maitland, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.